X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (45216) 45216
Newspaper Article (10522) 10522
Newsletter (8368) 8368
Book Review (8224) 8224
Publication (3771) 3771
Trade Publication Article (597) 597
Magazine Article (465) 465
Conference Proceeding (252) 252
Book Chapter (240) 240
Web Resource (187) 187
Transcript (128) 128
Book / eBook (60) 60
Dissertation (33) 33
Report (16) 16
Streaming Video (13) 13
Data Set (3) 3
Reference (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
melanoma (44900) 44900
index medicus (35022) 35022
humans (29872) 29872
cancer (21807) 21807
oncology (19093) 19093
animals (13950) 13950
female (12648) 12648
immunotherapy (11653) 11653
metastasis (11519) 11519
melanoma - drug therapy (11155) 11155
male (10785) 10785
care and treatment (10583) 10583
mice (10027) 10027
research (9973) 9973
tumors (9095) 9095
drug therapy (7944) 7944
middle aged (7416) 7416
cell line, tumor (7361) 7361
cancer therapies (7238) 7238
melanoma - pathology (7075) 7075
skin cancer (6601) 6601
apoptosis (6546) 6546
aged (6115) 6115
adult (5950) 5950
chemotherapy (5924) 5924
clinical trials (4991) 4991
medical research (4968) 4968
metastatic melanoma (4689) 4689
skin neoplasms - drug therapy (4609) 4609
antineoplastic agents - therapeutic use (4516) 4516
dermatology (4486) 4486
analysis (4367) 4367
health aspects (4274) 4274
immunology (4022) 4022
patients (4003) 4003
expression (4000) 4000
proteins (3741) 3741
mutation (3737) 3737
skin neoplasms - pathology (3726) 3726
pharmaceutical industry (3639) 3639
therapy (3635) 3635
antineoplastic agents - pharmacology (3557) 3557
cell biology (3534) 3534
antineoplastic agents (3501) 3501
pharmacology & pharmacy (3460) 3460
malignant-melanoma (3442) 3442
mice, inbred c57bl (3273) 3273
antimitotic agents (3261) 3261
treatment outcome (3200) 3200
medicine, research & experimental (3174) 3174
reports (3142) 3142
melanoma - therapy (3057) 3057
melanoma - metabolism (3055) 3055
melanoma - genetics (3012) 3012
drugs (2937) 2937
genetic aspects (2925) 2925
gene expression (2899) 2899
article (2817) 2817
biochemistry & molecular biology (2803) 2803
breast cancer (2768) 2768
prognosis (2737) 2737
medicine (2683) 2683
lung cancer (2678) 2678
studies (2674) 2674
ipilimumab (2624) 2624
cells (2566) 2566
lymphocytes (2539) 2539
apoptosis - drug effects (2531) 2531
kinases (2528) 2528
survival (2516) 2516
development and progression (2426) 2426
surgery (2413) 2413
melanoma - secondary (2383) 2383
immune system (2339) 2339
neoplasm metastasis (2337) 2337
cytotoxicity (2332) 2332
oncology, experimental (2294) 2294
antigens (2272) 2272
cell proliferation - drug effects (2270) 2270
melanoma, experimental - drug therapy (2235) 2235
metastases (2217) 2217
t cells (2203) 2203
tumor cells, cultured (2195) 2195
neoplasms - drug therapy (2192) 2192
melanoma - immunology (2191) 2191
aged, 80 and over (2167) 2167
abridged index medicus (2096) 2096
in-vivo (2056) 2056
antineoplastic combined chemotherapy protocols - therapeutic use (2045) 2045
research article (2035) 2035
medicine, experimental (1999) 1999
growth (1984) 1984
dendritic cells (1965) 1965
medical prognosis (1954) 1954
medicine & public health (1940) 1940
signal transduction (1927) 1927
in-vitro (1916) 1916
activation (1909) 1909
dose-response relationship, drug (1898) 1898
breast-cancer (1870) 1870
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (42) 42
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Scarborough Hospital - General (2) 2
Humber River Regional Hospital - Finch Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (64187) 64187
German (485) 485
French (298) 298
Russian (212) 212
Japanese (126) 126
Spanish (73) 73
Chinese (67) 67
Polish (51) 51
Italian (48) 48
Czech (28) 28
Hungarian (22) 22
Dutch (17) 17
Swedish (17) 17
Korean (11) 11
Danish (10) 10
Portuguese (8) 8
Turkish (7) 7
Norwegian (6) 6
Finnish (5) 5
Hebrew (5) 5
Croatian (4) 4
Ukrainian (3) 3
Bulgarian (2) 2
Romanian (2) 2
Serbian (2) 2
Slovak (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2017, Volume 75, pp. 169 - 178
Abstract Introduction With new systemic therapies demonstrating activity in melanoma brain metastasis, most of the previously reported stereotactic... 
Hematology, Oncology and Palliative Medicine | Stereotactic radiosurgery | Anti-PD-1 antibody | Targeted therapy | Brain metastasis | Immunotherapy | BRAF inhibitors | Melanoma | DABRAFENIB | MUTANT MELANOMA | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | UNTREATED MELANOMA | ONCOLOGY | POSITIVE MELANOMA | MUTATION | IPILIMUMAB | PHASE-2 TRIAL | VEMURAFENIB | Immunotherapy - methods | Humans | Middle Aged | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Tomography, X-Ray Computed | Positron-Emission Tomography | Young Adult | Brain Neoplasms - secondary | Aged, 80 and over | Adult | Female | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Radiosurgery - methods | Molecular Targeted Therapy - methods | MAP Kinase Kinase 1 - antagonists & inhibitors | Molecular Targeted Therapy - mortality | Melanoma - radiotherapy | Treatment Outcome | Combined Modality Therapy | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Adolescent | Skin Neoplasms | Aged | Radiosurgery - mortality | Melanoma - mortality | Metastasis | Patient outcomes | Surgery | Radiosurgery | Viral antibodies | Analysis | Antibodies | Brain | Therapy | Immunoglobulins | Brain cancer | MEK inhibitors | Multivariate analysis | Patients | Survival | Metastases | CTLA-4 protein | Inhibitors | Radiology | Age | Movement disorders | Index Medicus
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4774, 11/2017, Volume 14, Issue 11, pp. 647 - 647
Journal Article
OncoImmunology, ISSN 2162-4011, 09/2016, Volume 5, Issue 9, pp. e1214788 - e1214788
The anti-PD-1 antibodies nivolumab and pembrolizumab are active in metastatic melanoma; however, there is limited data on combining anti-PD-1 antibody and... 
radiotherapy | melanoma | Anti-pd-1 antibody | immunotherapy | RANDOMIZED-TRIAL | WHOLE-BRAIN RADIOTHERAPY | IMMUNOLOGY | TUMORS | CELL LUNG-CANCER | UNTREATED MELANOMA | STEREOTACTIC RADIOSURGERY | ONCOLOGY | RADIATION NECROSIS | NIVOLUMAB | BLOCKADE | IPILIMUMAB
Journal Article
Clinical Medicine, ISSN 1470-2118, 2/2014, Volume 14, Issue 1, pp. 47 - 53
This article explores the current and emerging therapies for skin disease, with a particular focus on chronic plaque psoriasis and metastatic malignant... 
biological therapies | malignant melanoma | Psoriasis | Drug Therapies in | tumour necrosis factor antagonists | atopic dermatitis
Journal Article
Nature Medicine, ISSN 1078-8956, 11/2015, Volume 21, Issue 11, pp. 1318 - 1325
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 368 - 372
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer(1,2). Here we show that targeted therapy with... 
CNS CELL-TYPES | MELANOMA | METASTASIS | MICROENVIRONMENT | TRANSLATIONAL PROFILING APPROACH | MULTIDISCIPLINARY SCIENCES | RAF INHIBITOR RESISTANCE | ACQUIRED-RESISTANCE | KINASE INHIBITORS | DRUG-RESISTANCE | CANCER CHEMORESISTANCE | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Clone Cells - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Proto-Oncogene Proteins c-fos - deficiency | Adenocarcinoma - metabolism | Neoplasm Metastasis - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Tumor Microenvironment - drug effects | Cell Survival - drug effects | Melanoma - pathology | Down-Regulation - drug effects | Enzyme Activation - drug effects | Adenocarcinoma - drug therapy | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Lung Neoplasms - secretion | Melanoma - secretion | Animals | Clone Cells - pathology | Metabolome - drug effects | Signal Transduction - drug effects | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adenocarcinoma - secretion | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Pharmaceutical research | Care and treatment | Oncology, Experimental | Dosage and administration | Research | Drug therapy | Drug resistance | Antineoplastic agents | Tumors | Cancer | Melanoma | Mutation | Metastasis | Kinases | Cancer therapies | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 2016, Volume 539, Issue 7629, pp. 443 - 447
Journal Article
Voprosy Onkologii, ISSN 0507-3758, 2017, Volume 63, Issue 3, pp. 358 - 367
Journal Article
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 05/2017, Volume 20, Issue 5, p. A11
OBJECTIVES: New treatments options are available for patients with advanced melanoma, which can vary in their efficacy, safety and dosing schedules. The... 
Drug abuse | Oncologists | Melanoma | Attitudes | Response rate | Critical incidents | Attributes | Oncology | Efficacy | Regression analysis | Dosage | Patients | Treatment | Skin melanoma | Discrete choice | Nurses | Mathematical models | Safety | Comparative analysis | Preferences | Drug therapy | Bayesian analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | SOLID TUMORS | RESPONSE CRITERIA | CELL ACTIVATION | IMMUNOTHERAPY | B7 FAMILY | ANTITUMOR IMMUNITY | CLINICAL ACTIVITY | PHASE-I | T-CELLS | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Lung | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 976 - 983
Journal Article